- Home
- WERN vs AUPH Comparison
WERN vs AUPH Comparison
Compare WERN & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WERN | AUPH |
|---|---|---|
| Founded | 1956 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | WERN | AUPH |
|---|---|---|
| Price | $29.95 | $15.69 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 4 |
| Target Price | ★ $26.23 | $17.25 |
| AVG Volume (30 Days) | 918.8K | ★ 1.6M |
| Earning Date | 10-30-2025 | 11-04-2025 |
| Dividend Yield | ★ 1.87% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.41 | ★ 0.55 |
| Revenue | ★ $2,991,440,000.00 | $265,808,000.00 |
| Revenue This Year | $1.18 | $21.22 |
| Revenue Next Year | $4.50 | $15.40 |
| P/E Ratio | $72.57 | ★ $28.12 |
| Revenue Growth | N/A | ★ 20.62 |
| 52 Week Low | $23.02 | $6.55 |
| 52 Week High | $40.16 | $16.48 |
Technical Indicators
Market Signals| Indicator | WERN | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 70.94 | 57.13 |
| Support Level | $25.20 | $15.41 |
| Resistance Level | $30.26 | $16.03 |
| Average True Range (ATR) | 1.05 | 0.52 |
| MACD | 0.59 | -0.16 |
| Stochastic Oscillator | 95.83 | 48.03 |
Price Performance
Historical ComparisonAbout WERN Werner Enterprises Inc.
Werner Enterprises Inc is a transportation and logistics company. The company has two reportable segments - Truckload Transportation Services and Werner Logistics. It derives majority of its revenue from full-truckload transportation services and geographically from United States.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.